Biomea Fusion

1. BMF-650 topline3Q 2026BMF-650 topline, 3Q 2026, material
2. Icovamenib topline4Q 2026Icovamenib topline, 4Q 2026, thesis-defining
3. Icovamenib COVALENT-211 topline4Q 2026Icovamenib COVALENT-211 topline, 4Q 2026, thesis-defining
4. Biomea Fusion corporate financing1Q 2027Biomea Fusion corporate financing, 1Q 2027, routine
5. Icovamenib COVALENT-212 topline2Q 2027Icovamenib COVALENT-212 topline, 2Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.